Nitazoxanide reduced inflammatory markers and mitochondrial changes in human retinal endothelial cells grown in high glucose.

MNRR1 protein levels were reduced in the diabetic retina of both humans and mice.

• Control and diabetic human retinal protein samples were analyzed by western blotting
• Control and diabetic mouse retinal samples were also analyzed by western blotting
• MNRR1 was localized to retinal endothelial cells (RECs) using immunostaining

NZT treatment significantly increased MNRR1 levels in RECs grown in both normal and high glucose conditions.

• RECs were grown in normal (5 mM) glucose and high (25 mM) glucose conditions
• MNRR1 levels were measured by western blotting
• NZT-treated cells had 'significantly higher MNRR1 levels' compared to untreated cells in both glucose conditions

NZT reduced inflammatory markers in RECs grown in high glucose.

• Inflammatory markers measured included high mobility group box 1 (HMGB1), interleukin 1β (IL-1β), and tumor necrosis factor α (TNF-α)
• Markers were assessed by western blotting in RECs grown in high (25 mM) glucose
• NZT treatment was associated with reduced levels of these inflammatory mediators

NZT increased the oxygen consumption rate (OCR) in RECs grown in high glucose, associated with an increase in Tom20.

• OCR was measured using a Seahorse XFe24 Bioanalyzer
• Measurements were performed in RECs under different glucose conditions with and without NZT treatment
• Increased OCR was associated with an increase in Tom20, a mitochondrial outer membrane protein used as a marker of mitochondrial mass
• Tom20 levels were measured by western blotting

MNRR1 was localized specifically to retinal endothelial cells within the retina.

• Localization was determined using immunostaining of retinal tissue
• This finding was used to support the relevance of REC-based in vitro experiments for studying diabetic retinopathy
• Both human and mouse retinal samples were used in the study